Myomo, Inc. (MYO)

Myomo's stock price has been volatile, with a significant decline of 69.97% from October 22, 2024, to October 21, 2025, and is down 82.8% year-to-date. Key events include a 162% revenue increase in Q1 2025 driven by higher revenue units and average selling price, and the launch of the MyoPro 2X. In Q2 2025, revenue increased by 28%, but full-year revenue guidance was revised downward due to challenges with lead quality and conversion, and increased operating expenses. Insiders have bought shares, while others sold shares earlier in the year. Myomo, Inc. was dropped from several indexes in June and September 2025. Analysts have a "Strong Buy" consensus rating with an average price target of $7.83.

Myomo's products and services exhibit some demand seasonality. Q2 2025 guidance indicated a slight sequential revenue decline from Q1 2025 due to "typical seasonality." Q4 2024 saw seasonal reductions in advertising spend, suggesting a pattern in marketing efforts tied to seasonal demand fluctuations. The company acknowledges and plans for these recurring variations in demand.

Myomo, Inc. is a wearable medical robotics company focused on designing, developing, and producing myoelectric orthotics for individuals with neuromuscular disorders and upper-limb paralysis, operating within the Medical Equipment, Supplies & Distribution sector. Its primary product, MyoPro, includes devices like the MyoPro 2X and the MyoPro 3 (under development), designed to restore function to weakened or paralyzed arms and hands.

Myomo, Inc. has a significant presence in the United States, with sales and clinical professionals across the country. Internationally, it has a notable business in Germany, with over 100 certified O&P clinics. Myomo is expanding globally with a joint venture in China (Jiangxi Myomo), anticipating a MyoPro launch by the end of 2025 pending NMPA approval.

Myomo's brand reputation has been indirectly influenced by operational challenges, including issues with lead generation due to changes in advertising policies and high denial rates from insurance plans. The company is expanding its O&P channel and providing clinical education through the Myomo Academy to differentiate its brand. Positive sentiment from stroke survivors using the MyoPro has been shared, highlighting the device's ability to improve arm and hand function.

Myomo, Inc.'s ownership is a mix of institutional, insider, and retail investors. Institutional investors hold approximately 6.53% to 13.35% of the stock, insiders hold 17.17%, and public and individual investors hold 6.83% to 69.47%. Major institutional shareholders include Rosalind Advisors, Inc., AIGH Capital Management LLC, and BlackRock, Inc. Gil Aharon owns the most shares among individual investors.